“More Market Than Medical” — The Oncologists Doubting Galleri as the FDA Panel Meets
FDA's first MCED advisory panel meets Sept 23 as NEJM publishes NHS-Galleri's missed primary endpoint (stage III/IV IRR 1.03). Verbatim skepticism from Drs. Bur…
Etcamah (Camizestrant) Is FDA Approved — and Some KOLs Still Agree With ODAC's No Vote
SERENA-6 KOL sentiment after the Etcamah (camizestrant) FDA approval: Tatiana Prowell, Angela DeMichele's ASCO plenary takeaways, Gyawali and other voices who s…
The DOL Launch: How Digital Opinion Leaders Ran Rasonque's Day One Product Launch
How KOLs and DOLs ran their own product launch for Rasonque (daraxonrasib) in pancreatic cancer: sequencing, patient selection, biomarkers, and patient educatio…
Key Learnings from COSMO 2026 for Digital Opinion Leaders and Patient Advocates
What the COSMO 2026 faculty slides teach oncology's digital voices and patient advocates: misinformation rates by platform, who patients trust, AI chatbot quali…
Gedatolisib (Revtorpyk) Is FDA Approved: What Breast Oncology KOLs Said on Day One
What breast oncology KOLs said within hours of the gedatolisib (Revtorpyk) FDA approval: doublet vs triplet, weekly-IV burden, and the 2.0-month control arm.